Author: Gubergrits N. B., President of the Ukrainian Club of Pancreatologists, member of the Council of the European Club of Pancreatologists and the International Association of Pancreatologists, elected President of the European Club of Pancreatologists (2016), multiple winner of the European Club of Pancreatologists and the International Association of Pancreatologists, Doctor of Medical Sciences, Professor
To obtain the necessary therapeutic effect of UDCA in the treatment of severe cholestatic liver diseases, a constant and long-term use of UDCA is necessary. In this regard, the highest requirements are imposed on the quality and bioavailability of the active substance in UDCA-containing preparations. The drugs that meet all the requirements include Choludexan. The high quality and bioavailability of UDCA, the optimal dosage of the active substance (300 mg), a convenient formulation for oral administration (in capsules), the absence of pronounced side effects, as well as the optimal price-quality ratio allow us to recommend Choludexan for the widest possible use in the treatment of cholestatic liver diseases. varying degrees of severity and at different stages of the development of pathology.
Published in the journal «District Doctor» april’2017